Northwest Biotherapeutics, Inc (NASDAQ:NWBO) Files An 8-K

0

In regard to the registered direct offering announced by the Company on October 21, 2016, the parties have mutually agreed to delay the completion of the transaction while the maximum number of shares that may be sold and the allocation among investors are confirmed.  The number of shares the Company may sell is limited in certain types of transactions pursuant to Nasdaq rules.  Determination of the number of shares may involve analyses based on circumstances of the current and prior financing transactions.  Certain investors from prior Company financings have a right, for a limited period of time, to participate in subsequent Company financings for up to fifty percent of each such subsequent financing.  Such participation rights would apply to the registered direct financing announced by the Company on October 21.  The number of shares which the prospective investor in this financing desired to purchase and the number of shares which the prior investors would have a right to purchase may exceed the number of shares the Company may sell in this type of transaction.  The Company is in discussions with Nasdaq to confirm the maximum number of shares that may be sold.  The Company plans to proceed with financing once this determination has been completed. The Company will make a new announcement at that time.